| Community building on the web: Secret strategies for successful online communities AJ Kim Peachpit press, 2006 | 1983 | 2006 |
| Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index JR Junutula, H Raab, S Clark, S Bhakta, DD Leipold, S Weir, Y Chen, ... Nature biotechnology 26 (8), 925-932, 2008 | 1482 | 2008 |
| Stereotype susceptibility in children: Effects of identity activation on quantitative performance N Ambady, M Shih, A Kim, TL Pittinsky Psychological science 12 (5), 385-390, 2001 | 964 | 2001 |
| Hepatocellular carcinoma: from diagnosis to treatment MS Grandhi, AK Kim, SM Ronnekleiv-Kelly, IR Kamel, MA Ghasebeh, ... Surgical oncology 25 (2), 74-85, 2016 | 474 | 2016 |
| Delayed neurotoxicity in primary central nervous system lymphoma AMP Omuro, LS Ben-Porat, KS Panageas, AK Kim, DD Correa, ... Archives of Neurology 62 (10), 1595-1600, 2005 | 296 | 2005 |
| Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry K Xu, L Liu, OM Saad, J Baudys, L Williams, D Leipold, B Shen, H Raab, ... Analytical biochemistry 412 (1), 56-66, 2011 | 188 | 2011 |
| Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates M Quik, N Parameswaran, SE McCallum, T Bordia, S Bao, A McCormack, ... Journal of neurochemistry 98 (6), 1866-1875, 2006 | 147 | 2006 |
| The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor GJ Burbach, KH Kim, AS Zivony, A Kim, J Aranda, S Wright, SM Naik, ... Journal of investigative dermatology 117 (5), 1075-1082, 2001 | 138 | 2001 |
| Recent developments and therapeutic strategies against hepatocellular carcinoma M Yarchoan, P Agarwal, A Villanueva, S Rao, LA Dawson, T Karasic, ... Cancer research 79 (17), 4326-4330, 2019 | 135 | 2019 |
| Characterization of the immune microenvironment in hepatocellular carcinoma M Yarchoan, D Xing, L Luan, H Xu, RB Sharma, A Popovic, TM Pawlik, ... Clinical Cancer Research 23 (23), 7333-7339, 2017 | 135 | 2017 |
| H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma JJ Joshi, H Coffey, E Corcoran, J Tsai, CL Huang, K Ichikawa, S Prajapati, ... Cancer research 77 (24), 6999-7013, 2017 | 130 | 2017 |
| New avenues for the treatment of Huntington’s disease A Kim, K Lalonde, A Truesdell, P Gomes Welter, PS Brocardo, ... International journal of molecular sciences 22 (16), 8363, 2021 | 111 | 2021 |
| Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer X Puyang, C Furman, GZ Zheng, ZJ Wu, D Banka, K Aithal, S Agoulnik, ... Cancer discovery 8 (9), 1176-1193, 2018 | 98 | 2018 |
| Impact of chronic liver disease and cirrhosis on health utilities using SF‐6D and the health utility index AA Dan, JB Kallman, R Srivastava, Z Younoszai, A Kim, ZM Younossi Liver Transplantation 14 (3), 321-326, 2008 | 96 | 2008 |
| Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia … DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Blood 134, 673, 2019 | 95 | 2019 |
| Community Building: Strategien für den Aufbau erfolgreicher Web-Communities AJ Kim Galileo Press, 2001 | 95 | 2001 |
| Enteropathogenic E. coli non‐LEE encoded effectors NleH1 and NleH2 attenuate NF‐κB activation SV Royan, RM Jones, A Koutsouris, JL Roxas, K Falzari, AW Weflen, ... Molecular microbiology 78 (5), 1232-1245, 2010 | 93 | 2010 |
| A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors A Patnaik, PM LoRusso, WA Messersmith, KP Papadopoulos, L Gore, ... Cancer chemotherapy and pharmacology 73, 951-960, 2014 | 87 | 2014 |
| A multidisciplinary toxicity team for cancer immunotherapy–related adverse events J Naidoo, J Zhang, EJ Lipson, PM Forde, K Suresh, KF Moseley, S Mehta, ... Journal of the National Comprehensive Cancer Network 17 (6), 712-720, 2019 | 86 | 2019 |
| Cyclic AMP/PKA‐dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin‐2 defective mice treated with sorafenib C Spirli, CM Morell, L Locatelli, S Okolicsanyi, C Ferrero, AK Kim, L Fabris, ... Hepatology 56 (6), 2363-2374, 2012 | 75 | 2012 |